In this issueFeature
Ozgene travel in January
The heart of the matter
Heart disease is one of the most common health conditions affecting individuals across the globe. Conditions such as hypoxia and ischemia can arise after a heart attack. Myocardial ischemia occurs when blood flow to the heart is reduced, preventing it from receiving enough oxygen. Scientific research into finding innovative treatments of myocardial ischemia is critical for improving the lives of those affected by heart disease.
Dr. Tobias Eckle is a physician and a scientist specialised in anaesthesiology, critical care medicine and cell biology. Dr. Eckle and his research team at the University of Colorado focus on identifying cellular adaptive mechanisms for ischemia and hypoxia. He has established several animal models to study acute lung injury, myocardial ischemia and whole body hypoxia. Results from Dr. Eckle’s current work have led to the identification of novel genes and new therapeutic concepts in the treatment of myocardial ischemia.
Dr. Eckle’s recent publication features mice generated by Ozgene to study the tissue-specific role of Adora2b (adenosine A2b receptor) in cardioprotection. Floxed Adora2b mice were crossed with Lyz2-Cre(+), VE-cadherin-Cre(+), or myosin-Cre(+) transgenic mice, respectively. The mice were exposed to periods of myocardial ischemia followed by reperfusion. Adora2b signalling was found to mediate different types of cardioprotection in a tissue-specific manner. These findings have implications for the use of Adora2b agonists in the treatment or prevention of myocardial injury by ischemia.
Please find the scientific publication on this study below in the publications section.
For more information on Dr. Eckle’s research, please visit the University of Colorado website.
For more information on Ozgene mouse models, please see Ozgene services.
Ozgene travel in January
Dr Roger Askew, our Principal Scientist in North America, will be visiting the Maryland and DC area between January 25-29, 2016. Please let us know if you would like to meet with Roger to discuss GEMs, mouse breeding, phenotyping, Vivarium management, or anything else we can help you with.
FEATURED - J Immunol. 2015 Aug 15.
Differential Tissue-Specific Function of Adora2b in Cardioprotection.
Seo SW, Koeppen M, Bonney S, Gobel M, Thayer M, Harter PN, Ravid K, Eltzschig HK, Mittelbronn M, Walker L6, Eckle T. - Kyung Hee University, Seoul, Republic of Korea; Ludwig Maximilians University Munich, Munich, Germany; University of Frankfurt, Frankfurt, Germany; University of Colorado Denver, Aurora, CO; Boston University School of Medicine, Boston, MA, USA. [read]
Behav Brain Res. 2015 Dec 19.
Neuronal overexpression of Glo1 or amygdalar microinjection of methylglyoxal is sufficient to regulate anxiety-like behavior in mice.
McMurray KM, Du X, Brownlee M, Palmer AA. - University of Chicago, Chicago; Albert Einstein College of Medicine, Bronx, NY; University of California San Diego, La Jolla, CA, USA. [read]
Brain Res. 2015 Dec 10.
Mice null for NEDD9 (HEF1) display extensive hippocampal dendritic spine loss and cognitive impairment.
Knutson DC, Mitzey AM, Talton LE, Clagett-Dame M. - University of Wisconsin-Madison, Madison, WI; University of California, Los Angeles, CA, USA. [read]
Frank's blog: 2015 in numbers
Another fantastic year is done and I’d like to share it with you by summarising it in numbers: 24-week timeline, 33% timeline improvement, 0 non-ES cell mice generated, 4 goGermline licenses granted, 30% growth in project numbers, 2 new services launched, 33 scientific publications, 110 years of experience... Want to find out more?
When all processes produce the desired result first time, the timeline can be as short as 18 weeks.
Our fastest conditional KO project took 24 weeks from vector construction to germline transmission.